BioCentury
ARTICLE | Deals

Viracta to start pivotal trial as public company following Sunesis merger, private placement

VCs, crossovers invest $105M ahead of EBV-associated cancer studies

December 1, 2020 12:36 AM UTC

An investor syndicate is backing Viracta with $105 million in fresh capital as the biotech goes public via a reverse merger and plans a pivotal trial of its lead therapy targeting EBV-positive lymphomas.

By merging with Sunesis Pharmaceuticals Inc. (NASDAQ:SNSS), Viracta Therapeutics Inc. will become a public company, fusing with what has effectively been a shell company since Sunesis elected in June not to advance its Btk program and began evaluating strategic alternatives...